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ABSTRACT
Objective: Generalized anxiety disorder (GAD) is a prevalent and debilitating psychiatric
condition in adolescence. Two effective forms of treatment are cognitive behavioral therapy
(CBT) and selective serotonin reuptake inhibitors. This pilot study examined changes in brain
function following each type of treatment in GAD.
Method: Subjects were 14 youth with GAD (7 had CBT, 7 received fluoxetine) and 10 age- and
gender-matched healthy peers. FMRI scans were acquired before and after treatment for patients,
and over two comparable time points for controls. During fMRI acquisition, a probe detection
task with emotional (angry, happy) and neutral faces allowed for assessment of neural response
to threat. Following previous research, region of interest analyses were performed in the right
ventrolateral prefrontal cortex (VLPFC).
Results: FMRI results showed increased VLPFC activation, relative to controls, in the
medication (t(15) = 3.01, p < 0.01) and CBT (t(15) = 3.22, p < 0.01) groups following treatment.
Conclusions: This study shows significant increase in VLPFC activation in response to angry
faces following treatment with CBT or fluoxetine for GAD. This is consistent with previous
research indicating that the VLPFC may facilitate effective responding to underlying neural
correlates of anxiety in other brain regions, such as the amygdala.
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INTRODUCTION
Generalized Anxiety Disorder (GAD) is a prevalent and debilitating psychiatric condition
characterized by excessive worry, hypervigilance, and apprehension about future events
(American Psychiatric Association, 2000). Anxiety disorders are associated with impairment in
daily life functioning (Ezpeleta et al. 2001) and predict high risk for future problems (Kessler et
al. 2008; Pine et al. 1998). Nevertheless, neurological correlates of GAD remain poorly
understood. There is a particular dearth of research on changes in brain circuitry associated with
improvements in GAD.
In adults, anxiety disorders are associated with increased activation in inferior frontal and
medial orbitofrontal cortices in response to anxiety provocation (Rauch et al. 1997). Adolescents
with GAD also show altered patterns of neural activation in ventral prefrontal cortex (vPFC).
Monk et al. (2006) found GAD patients showed greater ventrolateral (VLPFC) activation than
healthy peers when viewing angry faces. Further, VLPFC activation was negatively correlated
with their symptom severity, suggesting that VLPFC activation may serve a compensatory
function in GAD.
Two known, comparably effective treatments for GAD in children and adolescents are
cognitive behavioral therapy (CBT; Butler et al. 2006; Compton et al. 2004) and selective
serotonin reuptake inhibitors (SSRIs; Birmaher et al. 2003; Research Unit on Pediatric
Psychopharmacology Anxiety Study Group 2001; Walkup et al. 2008). CBT employs techniques
such as cognitive restructuring, relaxation, and self-monitoring to ease anxiety symptoms and
teach coping strategies (Lang 2004). Recent meta-analyses have consistently shown its
effectiveness in reducing anxiety symptoms in adult patient populations (Butler et al. 2006).
CBT shows moderate to large effect sizes in comparison to no treatment and nonspecific
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psychotherapies (Gould et al. 1997). Meta-analyses also show consistent evidence that the effects
of CBT are sustained over at least a 12-month period following successful treatment (DeRubeis
& Crits-Christoph 1998).
SSRIs have also been shown to effectively reduce symptoms in pediatric anxiety
disorders including GAD (Research Unit on Pediatric Psychopharmacology Anxiety Study
Group 2001; Seidel & Walkup 2006; Walkup et al. 2008). Treatment with fluoxetine versus
placebo is associated with significantly reduced anxiety symptoms and improved global
functioning (Birmaher et al. 2003). Additionally, continued treatment with fluoxetine versus no
medication following an initial period of medication treatment is associated with improved
outcomes one year later (Clark et al. 2005), indicating potential use in maintenance therapy.
Thus, although both CBT and SSRIs have demonstrated comparable efficacy as treatments for
GAD, the functional neurological changes that accompany the clinical improvement noted with
these treatments are unclear.
The research on the neural effects of psychotherapy on GAD specifically is sparse.
However, neuroimaging studies of the effects of psychotherapy in other major psychiatric
disorders have shown significant changes in patients’ functional activation following treatment
(for reviews see Linden 2006; Roffman et al. 2005). Roffman et al. (2005) note that despite wide
variations in type and number of diagnoses, type of psychotherapy, and method of neuroimaging,
these studies have shown a pattern of consistent attenuation of abnormal activation patterns in
regions associated with the pathophysiology of anxiety disorders. No known studies have
examined the neural correlates of CBT treatment for GAD. However, at least one study has
examined effects of CBT treatment in adult patients with major depressive disorder (MDD).
Goldapple et al. (2004) noted decreases in ventral and medial PFC activation while viewing sad
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faces following CBT treatment for MDD. As MDD and GAD are known to be highly comorbid
(Angold et al. 1999; Kessler et al. 2008), these results further implicate ventral and medial PFC
in treatment response for mood and anxiety disorders.
Studies on the neurological effects of SSRI treatment in GAD are similarly lacking. In
untreated adolescents with GAD, Monk et al. (2006) found that higher levels of VLPFC
activation were associated with fewer anxiety symptoms. As noted earlier, these results suggest
that the VLPFC may serve a compensatory function in GAD. The current study sought to
examine changes in brain function following the two types of effective treatments for GAD
youth. Based on previous findings (Monk et al. 2006), we expected that patients in each
treatment condition, relative to healthy peers, would show altered VLPFC activation to angry
faces following treatment. Increased activation following treatment could indicate compensatory
activation in the VLPFC. Decreased activation could indicate that less VLPFC activation was
needed to compensate for anxiety following successful treatment.

METHODS
Subjects
The sample consisted of 14 adolescents with GAD divided between two groups, those
treated with CBT (n = 7) and those treated with medication (n = 7), plus a comparison group (n =
10). Table 1 contains descriptive characteristics of each group. There were no significant
differences in the composition of the groups by age, gender, symptom severity or comorbid
diagnosis in the two treatment groups. 16 of the 24 subjects (6 from the CBT group, 6 from the
medication group, and 4 controls) were also included in a previous study (Monk et al 2006).
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Procedures
Patients’ diagnosis of GAD was determined using the Schedule for Affective Disorders
and Schizophrenia for School-Age Children Present and Lifetime Version (K-SADS-PL;
Kaufman et al. 1997). All patients received their choice of eight weeks of either CBT or
medication treatment. CBT treatment consisted of eight weekly sessions lasting 60-90 minutes
each and administered by a licensed clinical psychologist. Sessions focused on exposure and
skills training, following manualized curricula (Beidel et al. 2000; Kendall & Hedtke 2006).
Fluoxetine treatment was administered according to the protocol of the Research Unit on
Pediatric Psychopharmacology Anxiety Study Group (2001). An initial dose of 5mg/day was
increased every two weeks as recommended by a clinician up to a maximum of 40mg/day. FMRI
scans were performed before treatment and within approximately 2 weeks (15 +/- 7 days) of
treatment’s end. One potential source of difference between the two treatment groups was that
patients in the medication group were still receiving medication at the time of the second scan.
However, as discussed below, a comparison of the two groups showed no difference in their
VLPFC activation. Nonetheless, the groups were analyzed separately due to the qualitatively
different nature of the two treatments.

Anxiety Symptoms
Anxiety symptoms were measured at Time 1 and Time 2 using the Pediatric Anxiety
Rating Scale (PARS; Research Unit on Pediatric Psychopharmacology Anxiety Study Group
2002) by raters trained to achieve acceptable inter-rater reliability (ICC > 0.70). This 50-item
checklist shows good test-retest reliability and sensitivity to treatment-related changes in
symptoms.
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Behavioral Task and Analysis
A probe detection task (Mogg & Bradley 1999) was used to assess neural responses to
threat under controlled presentation circumstances and to allow comparison of the fMRI data
with Monk et al. (2006). In an event-related design, subjects viewed pairs of faces (angry/neutral,
happy/neutral and neutral/neutral) for 500 ms (Figure 1). Subjects responded by pressing a
button to an asterisk that was either on the same (congruent) or opposite (incongruent) side as the
emotional face. A total of 36 randomized trials for each condition were included. The main
analyses in the current study included only data from those trials in which an angry face was
present. Trials in which a happy face was present were also analyzed in order to determine the
specificity of any effects to angry faces.
Behavioral data were analyzed using paired-samples t-tests in SPSS. Participants had an
overall accuracy rate of 75% or greater (mean percentage correct = 94 +/- 6). Reaction time
differences of incongruent minus congruent trials provided a measure of attentional bias, such
that positive values indicated attentional bias toward the emotional face and negative values
indicated attentional bias away from the emotional face.

fMRI Procedures and Analysis
We used a GE 3T scanner to acquire images with 29 contiguous 3.3-mm axial slices
parallel to the anterior commissure/posterior commissure line. We used echo-planar, single-shot
gradient echo T2* weighting (TR=2300 msec; TE=23 msec; field of view=240 mm; 64×64
matrix; 3.3×3.75×3.75 mm voxel). High-resolution T1-weighted volumetric scans used a
magnetization-prepared gradient echo sequence (MP-RAGE): 180 1.0-mm axial slices; field of
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view=256 mm; number of excitations=1; TR=11.4 msec; TE=4.4 msec; matrix=256×256;
TI=300 msec; bandwidth 130 Hz/pixel=33 kHz for 256 pixels; in-plane resolution=1 mm3.
Functional imaging data were analyzed using AFNI software version 2.56b (Cox 1996;
available at http://afni.nimh.nih.gov/afni). Participants were excluded if there was motion greater
than 3mm in any direction. In order to mitigate movement, all images were registered to one
volume in each run. Data were smoothed using a 6-mm full width at half maximum isotropic
Gaussian filter. Incorrect trials and trials with reaction time < 200 msec or > 1000 ms were not
included in the fMRI analysis.
A random effects fMRI data analysis was conducted using a two-level procedure. At the
subject level, data from each subject were analyzed using multiple regression in AFNI’s
3dDeconvolve program. For the conditions of interest (angry/neutral congruent and incongruent),
vectors were created containing the onset time of each trial for each condition (blank trials were
modeled as an implicit baseline). Onset times for trials in which the subject did not respond or
responded incorrectly were modeled in a separate vector as a nuisance covariate. Vectors of
stimulus timing for each condition were transformed into reference waveforms of response
function using a gamma variate (Cohen 1997). Coefficients were thus produced for each
condition from each subject.
The primary effect of interest for the fMRI analysis was response to angry faces.
Therefore, contrasts were calculated to compare activation during trials in which an angry face
was present (both incongruent and congruent trials) relative to baseline (consistent with Monk et
al. 2006). Before performing the group level analysis, individual anatomical data sets were
converted to Talairach space. The underlying transformation was then applied to that same
individual’s functional data in order to convert those images as well. The group level analysis
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involved conducting a MANOVA analysis using the AFNI module GroupAna on the main
contrast of interest, angry versus baseline trials, to evaluate the neurophysiological response.
Two separate 2x2 (group x time) ANOVA analyses were performed. The CBT group and
medication group were analyzed separately, and each was compared to the control group. The
threshold of significance for all analyses was set at p < 0.01, uncorrected.

RESULTS
Behavioral Results
Each group’s mean reaction times on the behavioral task are presented in Table 2. We did
not test a specific hypothesis for the reaction time data, as this study was not designed to evaluate
changes in attentional bias because it was underpowered for this particular purpose. Attention
bias scores were examined but, unsurprisingly, these showed no significant results. The two
treatment groups did not significantly differ in their attentional bias to angry or happy faces at
Time 1 or Time 2. The treatment groups’ attentional bias scores also did not significantly differ
from controls at either time point. Finally, there was no significant change in attentional bias to
angry or happy faces from Time 1 to Time 2 in either treatment group.

Anxiety Symptoms
PARS scores did not differ significantly between the two treatment groups at Time 1
(t(12) = -.64, p > 0.05) or Time 2 (t(12) = 1.14, p > 0.05). Patients in both treatment groups
showed significant improvement in anxiety symptoms with treatment: CBT, t(6) = 5.91, p <
0.01; medication, t(6) = 3.94, p < 0.01.
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fMRI Results
Following previous work (Monk et al. 2006), we focused our fMRI analysis on the
response to angry faces. Specifically, we examined changes in brain activation between Time 1
and Time 2. The contrast of angry face trials versus baseline was analyzed separately in each
treatment group versus the control group. The medication group, relative to healthy comparisons,
showed a significant increase in VLPFC activation following treatment (Figures 2a and 2b). Two
clusters of activation were found, one more ventral (located at (31, 41, 0), t(15 )= 2.85, p < 0.01)
and one more dorsal (located at (35, 42, 14), t(15) = 3.01, p < 0.01).
The CBT group, relative to controls, also showed a significant increase from Time 1 to
Time 2 in VLPFC activation (Figure 3) to angry faces versus baseline (located at (41, 55, 1),
t(15) = 3.22, p < 0.01). In addition, surprisingly, this group also exhibited bilateral increases in
amygdala activation (right amygdala (27, -7, -12), t(15) = 2.74, p < 0.05; left amygdala (-17, -9, 14), t(15) = 2.54, p < 0.05). None of the clusters of activation was significantly correlated with
reductions in anxiety symptoms in either group.
To examine the specificity of these increases in right VLPFC activation, we examined the
change in activation from Time 1 to Time 2 in the contrast of happy faces versus baseline. Even
at a relaxed threshold of p < 0.05, neither treatment condition was associated with increased
VLPFC activation. Thus, the increase in right VLPFC activation following treatment for GAD
may be specific to viewing angry faces and not a general effect of viewing emotional faces.

DISCUSSION
Before considering the implications of these findings, it is important to note the many
limitations in the work presented here. For example, this study examined a very small number of
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subjects, divided into three groups, and patients presenting with GAD also exhibit frequent,
comorbid symptoms. Moreover, treatment assignment was based on subject choice, as opposed
to random assignment. As a result, these data should be considered as preliminary. Nevertheless,
the current data represent the only repeated fMRI study of any pediatric anxiety disorder.
Moreover, the data extend a wealth of other research generating a specific hypothesis about the
role of the VLPFC in attention and its relationship to pediatric anxiety (Pine, Guyer, &
Leibenluft 2009; Monk 2008). As a result, the findings, despite their preliminary nature, point to
important avenues for future research.
Consistent with our first hypothesis, the fMRI results showed increased VLPFC
activation, relative to controls, in both medication and CBT groups following treatment. The
observed increase in VLPFC activation following treatment for GAD is consistent with existing
research implicating this region in self-regulation of anxiety. Ochsner et al. (2004) found right
ventral PFC activity increased when healthy subjects were asked to voluntarily down-regulate
their negative emotions. Similarly, Phan et al. (2005) found right VLPFC activation increased
during down-regulation of negative emotions and reported that this activation was positively
correlated with intensity of the negative emotion. It is also consistent with Monk et al. (2006),
who showed that increased activation in this region was correlated with lower symptom severity
in a group of adolescents with GAD, suggesting a potential compensatory mechanism.
Although both are within the PFC, the regions of activation showing treatment-related
change appeared to differ between the CBT and medication groups. Nevertheless, a direct
comparison of the CBT and medication groups revealed no significant differences in the PFC.
Future, larger studies are needed that will allow these two groups to be contrasted with
reasonable statistical power. One additional, but not hypothesized, finding was a significant
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increase in bilateral amygdala activation in the CBT group following treatment. This result
warrants further study given its known importance in anxiety disorders (Monk et al. 2008,
McClure et al. 2007, Stein et al. 2002, Thomas et al. 2001).

Conclusions
Successful treatment of GAD with either CBT or fluoxetine in a sample of adolescents
was associated with increased activation in the VLPFC. Greater VLPFC activation may thus
constitute one mechanism by which these treatments act to decrease anxiety symptoms. To
further ascertain the neural correlates of treatment for GAD, future studies should examine the
replicability of these results in larger samples. Additional studies are also needed to determine
the stability of these effects after treatment has ended.
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Table 1. Sample characteristics
CBT

Age

Fluoxetine

Control

Statistic

13.4 (1.7)

13.3 (2.5)

14.5 (1.4)

F(2,21) = 1.09

Male

3

4

4

χ2(2) = .52

Female

4

3

6

Social Phobia

4

2

χ2(1) = 1.17

Separation Anxiety

5

5

χ2(1) = 0

ADHD

2

2

χ2(1) = 0

MDD

3

5

χ2(1) = 1.17

PARS, pre treatment

15.4 (3.2)

16.4 (2.5)

t(12) = -.64

PARS, post treatment

9.0 (4.8)

5.3 (7.2)

t(12) = 1.14

Gender

Comorbid Diagnosis

Anxiety Symptoms

Subject groups did not differ on age or gender, and treatment groups did not differ on comorbid
diagnoses or on anxiety symptom scores before or after treatment. CBT, cognitive behavioral
therapy. PARS, pediatric anxiety rating scale.
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Table 2. Mean reaction times (in ms) on behavioral task by subject group at Time 1 and Time 2

CBT
Time 1

Fluoxetine

Time 2

Time 1

Control

Time 2

Time 1

Time 2

Angry Congruent

543.93

528.23

556.44

483.69

530.13

512.57

Angry Incongruent

549.38

523.51

537.32

499.85

531.91

518.66

5.45

-4.73

-19.12

16.16

1.78

6.10

Happy Congruent

553.44

524.30

545.39

498.16

522.83

508.81

Happy Incongruent

552.79

521.73

537.19

498.52

533.86

513.92

0.65

2.57

8.21

-0.36

-11.03

-5.12

Angry Bias
(incongruent - congruent)

Happy Bias
(incongruent - congruent)

There were no significant differences in reaction time or attentional bias in any condition, either between groups at each time point or
within each group from Time 1 to Time 2. Reaction times to happy faces are presented for reference.
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Figure 1. Visual Task

Congruent: Threat &
Probe on Same Side

Duration (ms)

500

Event

Fixation

………

………
500

Threat

………

………
1100

………

Incongruent:
Threat & Probe on
Different Sides

Probe
(button press)

………

An initial fixation of 500ms was followed by pairs of emotional and neutral faces (angry/neutral
and happy/neutral) for 500ms. Subjects then responded by pressing a button to indicate the
position of an asterisk that was either on the same (congruent) or opposite (incongruent) side as
the emotional face.
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Figure 2. Increased VLPFC activation in patients treated with fluoxetine versus controls, Time 2
> Time 1.

a

b

Two clusters of activation were noted: a) Right VLPFC (31, 41, 0), t(15) = 2.85, p < 0.01, and b)
Right VLPFC (35, 42, 14), t(15) = 3.01, p < 0.01.
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Figure 3. Increased VLPFC activation in patients treated with CBT versus controls, Time 2 >
Time 1.

Increased activity from Time 1 to Time 2 in Right VLPFC (41, 55, 1), t(15) = 3.22, p < 0.01.
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